文献速递心脑血管急症

冠状动脉疾病患者抗血栓治疗疗效与安全性的性别差异:系统综述与荟萃分析

Sex related differences in efficacy and safety of antithrombotic therapy in patients with coronary artery disease: systematic review and meta-analysis.
PubMed 文献 · BMJ · 2025-07-29
一句话结论在已确诊冠状动脉疾病患者中,更强化与较不强化抗血栓治疗的疗效和安全性在女性和男性中一致,无性别交互作用。

该系统综述与荟萃分析纳入33项随机对照试验、共274 433例冠状动脉疾病患者(其中女性72 601例,中位比例25%),患者入组时间为1999年至2025年。采用试验内框架评估抗血栓治疗效应的性别异质性,性别特异性风险估计以风险比(95%CI)表示,试验水平的风险比比率采用逆方差模型合并。结果显示,更强化与较不强化抗血栓治疗相比,全因死亡在女性和男性中相对风险相当(交互作用HR 1.06,95%CI 0.94–1.19;交互作用P=0.33);心肌梗死风险在男女中均降低约15%(交互作用HR 1.05,95%CI 0.95–1.17;交互作用P=0.36);大出血风险在男女中均显著增加约40%(交互作用HR 0.99,95%CI 0.86–1.15;交互作用P=0.93)。结论认为,已确诊冠状动脉疾病患者的抗血栓治疗在女性和男性中提供一致的疗效和安全性结局。

要点

  • 更强化 vs 较不强化抗血栓治疗的全因死亡相对风险在女性和男性中相当,无性别交互作用(交互作用HR 1.06,95%CI 0.94–1.19;P=0.33)。
  • 更强化抗血栓治疗使心肌梗死风险在男女中均降低约15%,无性别交互作用(交互作用HR 1.05,95%CI 0.95–1.17;P=0.36)。
  • 更强化 vs 较不强化抗血栓治疗的大出血风险在男女中均显著增加约40%,无性别交互作用(交互作用HR 0.99,95%CI 0.86–1.15;P=0.93)。
  • 共33项随机对照试验、274 433例患者(女性72 601例,中位比例25%),全因死亡6018例,心肌梗死7558例,大出血4003例。

适用人群与场景

  • 已确诊冠状动脉疾病(coronary artery disease)的成年患者,来自33项随机对照试验,1999年至2025年入组。
  • 纳入标准:报告性别分层结局(缺血事件和大出血事件)并比较任何试验性 vs 对照抗血栓策略的随机对照试验。

研究设计与关键结果

  • 研究类型:系统综述与荟萃分析,纳入33项随机对照试验,共274 433例患者,其中女性72 601例(中位比例25%),入组时间1999年至2025年。
  • 全因死亡:22项试验中187 580例患者发生6018例死亡(更强化抗血栓治疗组3064例,较不强化治疗组2954例);更强化 vs 较不强化治疗的全因死亡相对风险在女性和男性中相当,无性别交互作用(交互作用HR 1.06,95%CI 0.94–1.19;交互作用P=0.33;I²=0.00%;异质性P=0.76)。
  • 心肌梗死:172 504例患者中发生7558例;更强化抗血栓治疗在男女中均与心肌梗死风险降低约15%相关(交互作用HR 1.05,95%CI 0.95–1.17;交互作用P=0.36;I²=14.05%;异质性P=0.28)。
  • 大出血:共发生4003例大出血事件(更强化治疗组2384例,较不强化治疗组1619例);更强化 vs 较不强化抗血栓治疗的大出血风险在男女中均显著增加约40%(交互作用HR 0.99,95%CI 0.86–1.15;交互作用P=0.93;I²=33.56%;异质性P=0.05)。

证据类型、等级与局限

  • 证据类型:系统综述与荟萃分析,纳入33项随机对照试验;系统综述注册号PROSPERO CRD42024560908。
  • 采用试验内框架评估抗血栓治疗效应的性别异质性,以避免生态学偏倚;性别特异性风险估计以风险比(95%CI)报告,试验水平风险比比率采用逆方差模型合并。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在已确诊冠状动脉疾病患者中,更强化与较不强化抗血栓治疗的疗效和安全性结局在女性和男性中一致,原文结论未据此给出按性别调整抗血栓治疗强度的推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To evaluate sex related differences in the treatment effect of antithrombotic therapy in patients with established coronary artery disease.

DESIGN: Systematic review and meta-analysis.

DATA SOURCES: Ovid Medline and Embase databases from inception to April 2025.

INCLUSION CRITERIA: Included studies were randomised controlled trials reporting sex stratified outcomes, including ischaemic and major bleeding events, and comparing any experimental versus control antithrombotic strategy in coronary artery disease.

DATA EXTRACTION AND SYNTHESIS: Two reviewers extracted data and assessed the risk of bias. To avoid ecological bias, a within trial framework was developed to evaluate sex related heterogeneity in the treatment effect of antithrombotic therapies. Sex specific risk estimates were reported as hazard ratios with 95% confidence intervals, whereas trial level ratios of hazard ratios were pooled with an inverse variance model.

RESULTS: A total of 33 trials enrolling 274 433 participants, of which 72 601 (median proportion 25%) were women, were included. Patients were enrolled between 1999 and 2025. A total of 6018 deaths occurred in 187 580 patients across 22 trials (3064 deaths in patients using more intensive antithrombotic therapies and 2954 in those using less intensive therapies). The relative risk of all cause death was comparable for more intensive versus less intensive antithrombotic therapies in both women and men, without sex based interaction (interaction hazard ratio 1.06, 95% confidence interval 0.94 to 1.19; P for interaction=0.33; I2=0.00%; P for heterogeneity=0.76). 7558 myocardial infarctions occurred among 172 504 patients. More intensive antithrombotic therapies were associated with a reduced risk of myocardial infarction by ~15% in both men and women (interaction hazard ratio 1.05, 0.95 to 1.17; P for interaction=0.36; I2=14.05%; P for heterogeneity=0.28). Conversely, major bleeding was significantly increased by ~40% for more intensive versus less intensive antithrombotic therapies irrespective of sex (interaction hazard ratio 0.99, 0.86 to 1.15; P for interaction=0.93; I2=33.56%; P for heterogeneity=0.05). Overall, 4003 major bleeding events occurred (2384 in patients using more intensive therapies and 1619 in those using less intensive therapies).

CONCLUSIONS: Antithrombotic therapies in patients with established coronary artery disease provided consistent efficacy and safety outcomes in women and men.

SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42024560908.

来源:BMJ,查看原文。版权归原作者所有。

参考来源

  1. Piccolo R, Laino A, Vitale AP, et al. Sex related differences in efficacy and safety of antithrombotic therapy in patients with coronary artery disease: systematic review and meta-analysis. BMJ. 2025. PMID: 40730387. doi:10.1136/bmj-2024-082974

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。